Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Study demonstrates associations between COVID-19 symptom presentation and antibody assay reactivity

Researchers tested convalescent sera from individuals who had recovered from SARS-CoV-2 infection to demonstrate an association between antibody response and reported COVID-19 symptoms.

14 Feb 2022

Differences in infection with Omicron or Delta SARS-CoV-2 variants among vaccinated population from the UK

In a recent study, researchers demonstrated that COVID-19 symptoms varied between cases of SARS-CoV-2 Omicron and Delta variants of concern.

14 Feb 2022

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

A new study was based on the hypothesis that competitively inhibiting cellular furin and selectively targeting SARS-CoV-2 in the infected viral-producing cells is critical for therapeutic specificity.

14 Feb 2022

Study explores the social impact of COVID-19 symptoms among female long haulers

A new study analyzed the impact of long-COVID on women long haulers with respect to various aspects of their social life.

14 Feb 2022

Study shows expression of viral proteases may be used to quantitate SARS-CoV-2 infected cells

A new study describes a new method to quantify SARS-CoV-2 infection, which is much simpler and faster compared to existing methods.

14 Feb 2022

Study finds mRNA vaccines induce poor neutralizing antibody response against SARS-CoV-2 variants in dialysis patients

Scientists studied plasma samples from 130 hemodialysis (HD) and 13 peritoneal dialysis patients and showed a poor neutralizing and rapidly decaying antibody response to mRNA vaccines in such individuals.

14 Feb 2022

How a third booster BNT162b2 dose impacts anti-spike antibody levels

A new study aimed to investigate the mechanism by which the third booster BNT162b2 dose impacts anti-S levels.

14 Feb 2022

mRNA-1273 and mRNA-1273.529 Omicron-specific boosters highly effective in mouse model

In a study posted to the bioRxiv* preprint server, a team of researchers from the United States evaluated the protective effect of the preclinical version of the current Moderna Omicron-targeted mRNA-1273.529 vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 Omicron infection in mice.

14 Feb 2022

Study looks at potential impact of BBIBPCorV and CoronaVac SARS-CoV-2 vaccines on thyroid

In a recent study posted to Preprints with The Lancet* server, a team of researchers from China performed a serology study of thyroid function and antithyroid antibody levels in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-vaccinated recipients and further evaluated their correlation with SARS-CoV-2 neutralizing antibodies (NAbs) levels.

14 Feb 2022

Nitazoxanide shows promise for COVID-19 treatment in animal model

In a recent study posted to the bioRxiv* pre-print server, researchers demonstrated that Nitazoxanide (NTZ), an oral drug, broadly inhibits replication of several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in preclinical models of infection.

13 Feb 2022

Testes found to be a viral reservoir for SARS-CoV-2 replication

In a recent study posted to the medRxiv* pre-print server, researchers used a suite of methods to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the testis of patients who died from coronavirus disease 2019 (COVID-19) to gain insights into SARS-CoV-2 tropism inside testis and its impact on male fertility.

13 Feb 2022

Wearable sensors for COVID-19 mitigation

In a recent study posted to the medRxiv* pre-print server, researchers simulated several wearable sensor deployment scenarios to demonstrate the potential of digital contact tracing technology in mitigating the coronavirus disease 2019 (COVID-19) pandemic.

13 Feb 2022

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

A recent paper by researchers from Australia, currently available on the medRxiv* preprint server, shows how Immunoglobulin A (IgA) antibodies in individuals who were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to the neutralization of the virus and its variants, even though this response is heterogeneous and less potent when compared to IgG antibodies.

13 Feb 2022

Looking into the long-COVID brain

Neurological issues, ranging from memory lapses to trouble with attention, have been widely reported after recovery from severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection. Unfortunately, there is limited information about pathways to recovery after severe COVID hospitalization. Now, a prospective study of 4,491 patients hospitalized with COVID suggests neurological recovery can take at least a year. The study is currently available on the medRxiv* preprint while awaiting peer review.

13 Feb 2022